{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:08:29Z","timestamp":1792066109993,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003397","name":"Huazhong University of Science and Technology","doi-asserted-by":"publisher","award":["LLHBCH2023YN-044"],"award-info":[{"award-number":["LLHBCH2023YN-044"]}],"id":[{"id":"10.13039\/501100003397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2021-21-15"],"award-info":[{"award-number":["320.6750.2021-21-15"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clbc.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:21:41Z","timestamp":1752607301000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Study on Different Staining Platforms for HER2 Cytoplasmic Granular Staining Pattern in Pure Apocrine Carcinoma of the Breast"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5123-624X","authenticated-orcid":false,"given":"Xue-Xue","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-8445","authenticated-orcid":false,"given":"Jun-Qiu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clbc.2025.07.016_bib0001","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clbc.2025.07.016_bib0002","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1158\/1078-0432.CCR-08-1056","article-title":"HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer","volume":"14","author":"Press","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.clbc.2025.07.016_bib0003","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.07.016_bib0004","unstructured":"Chinese Society of Clinical Oncology. Breast cancer guidelines (2024 Edition) [M]. Chinese Society of Clinical Oncology Guidelines Working Committee. Beijing: People's Medical Publishing House; 2024."},{"issue":"9","key":"10.1016\/j.clbc.2025.07.016_bib0005","first-page":"799","article-title":"Advances and challenges in detection of HER2 low expression in breast cancer","volume":"51","author":"Liu","year":"2022","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.clbc.2025.07.016_bib0006","unstructured":"ENHERTU\u00ae Granted breakthrough therapy designation in U.S. for certain patients with HER2 low or HER2 ultralow metastatic breast cancer. Retrieved August 19, 2024, https:\/\/www.businesswire.com\/news\/home\/20240818195338\/en\/ENHERTU%C2%AE-Granted-Breakthrough-Therapy-Designation-in-U.S.-for-Certain-Patients-with-HER2-Low-or-HER2-Ultralow-Metastatic-Breast-Cancer."},{"issue":"4","key":"10.1016\/j.clbc.2025.07.016_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.016_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-025-02001-0","article-title":"Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China","volume":"27","author":"Lv","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2025.07.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clbc.2025.07.016_bib0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00428-022-03378-5","article-title":"Comparison of HercepTest\u2122 mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2\/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status","volume":"481","author":"R\u00fcschoff","year":"2022","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.clbc.2025.07.016_bib0011","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jclinpath-2012-201078","article-title":"Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012","volume":"66","author":"Tan","year":"2013","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.016_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.32074\/1591-951X-1-20","article-title":"Histological type and typing of breast carcinomas and the WHO classification changes over time","volume":"112","author":"Cserni","year":"2020","journal-title":"Pathologica"},{"issue":"4","key":"10.1016\/j.clbc.2025.07.016_bib0013","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/j.clbc.2021.12.009","article-title":"An update on the molecular and clinical characteristics of apocrine carcinoma of the breast","volume":"22","author":"Vranic","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.07.016_bib0014","unstructured":"Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. Lyon: IARC Press, 2012."},{"issue":"5","key":"10.1016\/j.clbc.2025.07.016_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/modpathol.2010.50","article-title":"EGFR and HER-2\/neu expression in invasive apocrine carcinoma of the breast","volume":"23","author":"Vranic","year":"2010","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.clbc.2025.07.016_bib0016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.clbc.2025.07.016_bib0017","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/gs-22-248","article-title":"Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses","volume":"11","author":"Xiao","year":"2022","journal-title":"Gland Surg"},{"issue":"3","key":"10.1016\/j.clbc.2025.07.016_bib0018","first-page":"169","article-title":"[Guideline for HER2 detection in breast cancer, the 2019 version]","volume":"48","year":"2019","journal-title":"Chin J Pathol"},{"issue":"12","key":"10.1016\/j.clbc.2025.07.016_bib0019","first-page":"1288","article-title":"Branch of Oncologist; Chinese Medical Doctor Association. Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)","volume":"44","author":"International Medical Society","year":"2022","journal-title":"Chin J Oncol"},{"key":"10.1016\/j.clbc.2025.07.016_bib0020","series-title":"WHO classification of tumours: breast tumours","first-page":"131","article-title":"Carcinoma with apocrine differentiation","year":"2019"},{"key":"10.1016\/j.clbc.2025.07.016_bib0021","volume":"81","author":"Bardia","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2025.07.016_bib0022","unstructured":"Food and Drug Administration. (2024). FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. Retrieved July 7, 2024, from https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"issue":"11","key":"10.1016\/j.clbc.2025.07.016_bib0023","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/jclinpath-2013-201647","article-title":"False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma","volume":"66","author":"Nunes","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.clbc.2025.07.016_bib0024","doi-asserted-by":"crossref","unstructured":"Lucas E, Jabbar SB, Molberg K, et al. Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with fluorescent In situ hybridization in breast carcinoma. Appl Immunohistochem Mol Morphol,2019,27(6):403-409.","DOI":"10.1097\/PAI.0000000000000646"},{"issue":"11","key":"10.1016\/j.clbc.2025.07.016_bib0025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/14737140.2023.2171993","article-title":"The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer","volume":"24","author":"Schlam","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.clbc.2025.07.016_bib0026","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-022-06578-4","article-title":"HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome","volume":"193","author":"Skenderi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.clbc.2025.07.016_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229031","article-title":"Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: comparison with immunohistochemistry analysis","volume":"15","author":"Seung","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.016_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12967-017-1195-7","article-title":"Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases","volume":"15","author":"Zoppoli","year":"2017","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.clbc.2025.07.016_bib0029","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1186\/s12885-018-5172-1","article-title":"A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study","volume":"18","author":"Hicks","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925002113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925002113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:27:22Z","timestamp":1781076442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1526820925002113"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.07.016","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study on Different Staining Platforms for HER2 Cytoplasmic Granular Staining Pattern in Pure Apocrine Carcinoma of the Breast","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}